{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-127184","form_type":"8-K","ticker":null,"cik":"0001260990","company_name":"Oncternal Therapeutics, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.922603+00:00","generated_at":"2026-05-30T00:17:33.809313+00:00","sec_items":["2.05","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Oncternal Therapeutics cuts remaining workforce; retains 4 part-time employees for strategic alternatives","bullets":["Workforce reduction of all remaining employees effective Dec 2, 2024; only 4 retained part-time.","Estimated severance and termination costs of ~$2.4M, primarily recognized in Q4 2024.","CEO James B. Breitmeyer and officer Richard G. Vincent transition to 50% part-time effective Dec 2.","Board unanimously approved reduction on Nov 13; company exploring strategic alternatives, including sale or dissolution."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-127184","json":"https://secwatch.observer/filing/0000950170-24-127184.json","markdown":"https://secwatch.observer/filing/0000950170-24-127184.md","text":"https://secwatch.observer/filing/0000950170-24-127184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024127184/0000950170-24-127184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024127184/onct-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:17:33.809313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bac3233336","claim":"Richard G. Vincent changed role as other_named_officer at Oncternal Therapeutics, Inc..","evidence_excerpt":"In connection with the workforce reduction, James B. Breitmeyer, M.D., Ph.D. and Richard G. Vincent will transition to part-time employment status, reducing their time commitment to 50% of their current duties effective December 2, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024127184/0000950170-24-127184-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned to part-time employment status"}],"fact_type":"executive_change"},{"claim_id":"f5afbe191e","claim":"James B. Breitmeyer changed role as Chief Executive Officer at Oncternal Therapeutics, Inc..","evidence_excerpt":"In connection with the workforce reduction, James B. Breitmeyer, M.D., Ph.D. and Richard G. Vincent will transition to part-time employment status, reducing their time commitment to 50% of their current duties effective December 2, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024127184/0000950170-24-127184-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned to part-time employment status"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"67460310a91a5e12e18fa08411e2b2ffaf67b53d","claim":"Oncternal Therapeutics, Inc. announced a restructuring with charges of approximately $2.4 million (workforce reduction of its remaining employees).","evidence_excerpt":"Oncternal currently estimates that it will incur charges associated with the workforce reduction of all of its remaining employees of approximately $2.4 million primarily related to employee severance payments, benefits and related termination costs","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024127184/0000950170-24-127184-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2.4 million"},{"label":"Headcount","value":"workforce reduction of its remaining employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}